Clinical Trials | February 25, 2026
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Akero became a wholly owned subsidiary of Novo Nordisk
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Subscribe To Our Newsletter & Stay Updated
